Advanced differentiated thyroid cancer: when to stop radioiodine?-Reference-Cited by-同舟云学术

Advanced differentiated thyroid cancer: when to stop radioiodine?

Published:2019-10 Issue:3 Volume:63 Page:
ISSN:1824-4785
Container-title:The Quarterly Journal of Nuclear Medicine and Molecular Imaging
language:
Short-container-title:Q J Nucl Med Mol Imaging

Author:

Giovanella Luca,van Nostrand Douglas

Publisher

Edizioni Minerva Medica

Subject

Radiology Nuclear Medicine and imaging

Link

https://www.minervamedica.it/pdf.php?cod=R39Y2019N03A0267

Reference17 articles.

1. Van Nostrand D. 131I Treatment of Distant Metastases. In: Wartofsky L, Van Nostrand D, et al. Thyroid cancer: a comprehensive guide to clinical management. Third Edition. New York: Springer; 2016. p. 595-627.

2. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

3. Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications

4. Definition and management of radioactive iodine-refractory differentiated thyroid cancer: recommendations by an international expert panel;Schlumberger M;Lancet Endo,2014

5. Evolving Approaches in Managing Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostics of Thyroid Cancer;Seminars in Nuclear Medicine;2024-07

2. Role of FDG PET/CT in Management of Patients with Prostate Cancer;Seminars in Nuclear Medicine;2024-01

3. Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer;Cancers;2023-08-27

4. Redifferentiation of Differentiated Thyroid Cancer: Clinical Insights from a Narrative Review of Literature;Thyroid;2023-06-01

5. Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?;Endocrine;2023-05-16